Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...
The cold, dry air of winter brings challenges for those with chronic hand eczema. Chronic hand eczema (CHE), defined as hand ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
Dr Philippa Kaye answers: Spots on the top of the arms is often due to a skin condition called keratosis pilaris.
Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...
A Sydney woman has explained how these types of extreme January weather events wreak serious havoc on the skin - and even ...
A mother-of-two was diagnosed with lobular breast cancer after feeling a sharp pain in her breast during a hot yoga session.
It’s lightweight and has a cooling feel ...
You are about to be everyone's BFF on outings when you whip out the mouthwash tablets and this migraine-soothing rollerball.
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Kymera Therapeutics reported on Monday that, for the second time this year, it has ...
Forbes contributors publish independent expert analyses and insights. Bruce Y. Lee, M.D., MBA, covers health, medicine, wellness and science A big reason for the many misconceptions that exist about ...
An international team of investigators has reported results from the first Phase III clinical trials of rocatinlimab, a novel treatment for moderate-to-severe atopic dermatitis (eczema). The findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback